Glycorex Transplantation AB (publ) (NGM:GTAB.B)
1.755
-0.015 (-0.85%)
At close: Nov 18, 2026
Glycorex Transplantation AB Company Description
Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas.
It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood.
The company’s principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transplantation procedures.
It serves in the United Kingdom, Australia, Scandinavia, Spain, Germany, and Austria. Glycorex Transplantation AB (publ) was incorporated in 1995 and is headquartered in Lund, Sweden.
Glycorex Transplantation AB (publ)
| Country | Sweden |
| Founded | 1995 |
| Industry | Surgical and Medical Instruments and Apparatus |
| Employees | 20 |
| CEO | Carl-Magnus Schultz |
Contact Details
Address: ScheelevAegen 27 Lund, 223 63 Sweden | |
| Phone | 46 4 62 86 52 30 |
| Website | glycorex.com |
Stock Details
| Ticker Symbol | GTAB.B |
| Exchange | Nordic Growth Market |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0000524530 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Carl-Magnus Schultz | Chief Executive Officer |